Abstract
Chronic kidney disease (CKD) is characterized by the retention of solutes named uremic toxins, which strongly associate with high morbidity and mortality. Mounting evidence suggests that targeting uremic toxins and/or their pathways may decrease the risk of cardiovascular disease in CKD patients. Dialysis therapies have been developed to improve removal of uremic toxins. Advances in our understanding of uremic retention solutes as well as improvements in dialysis membranes and techniques (HDx, Expanded Hemodialysis) will offer the opportunity to ameliorate clinical symptoms and outcomes, facilitate personalized and targeted dialysis treatment, and improve quality of life, morbidity and mortality.
Highlights
In the recent years, there have been many significant achievements in the management of end-stage renal disease (ESRD) patients on dialysis
The most recent and promising advance in the field of haemodialysis is represented by the development of medium-cut-off (MCO) high
The most recent and promising advance in the field of haemodialysis is represented by the development of medium-cut-off (MCO) high-retention-onset membranes
Summary
There have been many significant achievements in the management of end-stage renal disease (ESRD) patients on dialysis. These uremic toxins have a large spectrum of chemical and functional variety and are roughly divided in 4 groups: cytokines, adipokines, immune-related proteins, and growth factors and hormones Their increased pathological concentration in ESRD patients, due to kidney failure, seems to be responsible of decreased chemiotaxis and immune-defence, atherogenesis, cardiac hypertrophy, and anorexia, accounting for the MM detrimental roles in inflammation, calcification, and cardiovascular morbidity and mortality. The introduction of MCO membranes in clinical practice is one of the most relevant innovations in the field of haemodialysis These filters are capable of removing MM uraemic toxins without the need for high convective volumes and without a significant albumin loss [3]. We analyze the scientific research that contributes to elucidate the potential benefits given by the better removal of uremic toxins and their pathogenic effect in particular in the processes of inflammation and calcification in experimental models
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
